Deoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemia

European Journal of Haematology

Volumn 69, Issue 3, 2002, Pages 171-178

  Veuger, Marjan J T ^a   Honders, M Willy ^a   Willemze, Roel ^a   Barge, Renée M Y ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukemia; Cytarabine resistance; dCK activity; dCK mRNA expression; dCK protein expression

Indexed keywords

CYTARABINE; DEOXYCYTIDINE KINASE; MESSENGER RNA;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLAST CELL; BLOOD SAMPLING; CANCER RECURRENCE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WILD TYPE;

ACUTE DISEASE; ANTIMETABOLITES, ANTINEOPLASTIC; CYTARABINE; DEOXYCYTIDINE KINASE; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HUMANS; LEUKEMIA, MYELOID; RECURRENCE;

EID: 0036757209     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2002.02785.x     Document Type: Article

References (26)

1. Owens JK, Shewach DS, Ullman B, Mitchell BS. Resistance to 1-β-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res 1992;52:2389-2393.
2. Bhalla K, Nayak R, Grant S. Isolation and characterization of a deoxycytidine kinase- deficient human promyelocytic leukemic cell line highly resistant to 1-β-Darabinofuranosylcytosine. Cancer Res 1984;44:5029-5037.
3. Dumontet C, Fabianowska-Majewska K, Mantincic D, et al. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol 1999;106:78-85.
4. Kees UR, Ford J, Dawson VM, Piall E, Aherne GW. Development of resistance to 1-βD-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: Analysis of resistance mechanism in established cell lines. Cancer Res 1989;49:3015-3019.
5. Stegmann AP, Honders MW, Hagemeijer A, Hoebee B, Willemze R, Landegent JE. In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza2′-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene. Ann Hematol 1995;71:41-47.
6. Flasshove M, Strumberg D, Ayscue L, et al. Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabi-noside. Leukemia 1994;8:780-785.
7. van den Heuvel-Eibrink MM, Wiemer EA, Kuijpers M, Pieters R, Sonneveld P. Absence of mutations in the deoxycytidine kinase (dCK) gene in patients with relapsed and/or refractory acute myeloid leukemia (AML). Leukemia 2001;15:855-856.
8. Veuger MJT, Honders MW, Landegent JE, Willemze R, Barge RMY. High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia. Blood 2000;96:1517-1524.
9. Veuger MJT, Heemskerk MH, Honders MW, Willemze R, Barge RMY. Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells. Blood 2002;99:1373-1380.
10. Hatzis P, Al Madhoon AS, Jullig M, Petrakis TG, Eriksson S, Talianidis I. The intracellular localization of deoxycytidine kinase. J Biol Chem 1998;273:30239-30243.
11. Veuger MJT, Honders MW, Landegent JE, Willemze R, Barge RMY. A novel RT-PCR-based protein activity truncation assay for direct assessment of deoxycytidine kinase in small numbers of purified leukemic cells. Leukemia 2000;14:1678-1684.
12. Mensink E, van de Locht A, Schattenberg A, Linders E, Schaap N, Geurts VK, De Witte T. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol 1998;102:768-774.
13. Johansson M, Karlsson A. Differences in kinetic properties of pure recombinant human and mouse deoxycytidine kinase. Biochem Pharmacol 1995;50:163-168.
14. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
15. Cheng YC, Domin B, Lee LS. Human deoxycytidine kinase. Purification and characterization of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia patients. Biochim Biophys Acta 1977;481:481-492.
16. Stegmann AP, Honders MW, Willemze R, Landegent JE. De novo induced mutations in the deoxycytidine kinase (dck) gene in rat leukemic clonal cell lines confer resistance to cytarabine (AraC) and 5- aza-2′-deoxycytidine (DAC). Leukemia 1995;9:1032-1038.
17. Ruiz van Haperen, V, Veerman G, Eriksson S, et al. Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res 1994;54:4138-4143.
18. Kobayashi T, Kakihara T, Uchiyama M, Fukuda T, Kishi K, Shibata A, Low expression of the deoxycytidine kinase (dCK) gene in a 1-β-D-arabinofuranosylcytosine-resistant human leukemic cell line KY-Ra. Leuk Lymphoma 1994;15:503-505.
19. Kakihara T, Fukuda T, Tanaka A, et al. Expression of deoxycytidine kinase (dCK) gene in leukemic cells in childhood: Decreased expression of dCK gene in relapsed leukemia. Leuk Lymphoma 1998;31:405-409.
20. Spasokoukotskaja T, Arner Es, Brosjo O, et al. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues. Eur J Cancer 1995;31A:202-208.
21. Singhal RL, Yeh YA, Szekeres T, Weber G. Increased deoxycytidine kinase activity in cancer cells and inhibition by difluorodeoxycytidine. Oncol Res 1992;4:517-522.
22. Csapo Z, Sasvari-Szekely M, Spasokoukotskaja T, Talianidis I, Eriksson S, Staub M. Activation of deoxycytidine kinase by inhibition of DNA synthesis in human lymphocytes. Biochem Pharmacol 2001;61:191-197.
23. Chiba P, Tihan T, Szekeres T, et al. Concordant changes of pyrimidine metabolism in blasts of two cases of acute myeloid leukemia after repeated treatment with ara-C in vivo. Leukemia 1990;4:761-765.
24. Schroder JK, Kirch C, Seeber S, Schutte, J. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br J Haematol 1998;103:1096-1103.
25. Tattersall MH, Ganeshaguru K, Hoffbrand AV. Mechanisms of resistance of human acute leukaemia cells to cytosine arabinoside. Br J Haematol 1974;27:39-46.
26. Colly LP, Peters WG, Richel D, Arentsen-Honders MW, Starrenburg CW, Willemze R. Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myelogenous leukemia. Semin Oncol 1987;14:257-261.